(0.01%) 5 479.25 points
(0.00%) 38 819 points
(0.06%) 19 933 points
(0.26%) $80.54
(1.00%) $2.82
(0.12%) $2 331.70
(-0.38%) $29.28
(-0.10%) $969.90
(0.04%) $0.932
(-0.10%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis...
Stats | |
---|---|
Šios dienos apimtis | 2.78M |
Vidutinė apimtis | 6.37M |
Rinkos kapitalizacija | 8.18M |
EPS | $-0.140 ( Q1 | 2024-05-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.257 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.131 (14.81%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-04-15 | Desparbes Eric | Buy | 231 693 | Common Stock |
2022-04-15 | Neumann Clarke | Buy | 184 843 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 2 transactions |
Buy: 416 536 | Sell: 0 |
Tūris Koreliacija
Progenity, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ENNV | 0.946 |
TVACW | 0.926 |
SRNGW | 0.916 |
HJLIW | 0.904 |
AZRX | 0.902 |
LSAQ | 0.887 |
XPDI | 0.88 |
OBLN | 0.878 |
SRNG | 0.867 |
TCDA | 0.856 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
FTIV | -0.909 |
SCOB | -0.881 |
MSAC | -0.874 |
BCOR | -0.861 |
LGACU | -0.859 |
ITQ | -0.842 |
CTAQ | -0.831 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Progenity, Inc. Koreliacija - Valiuta/Žaliavos
Progenity, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $4 000.00 |
Bruto pelnas: | $-551 000 (-13 775.00 %) |
EPS: | $-7.87 |
FY | 2023 |
Pajamos: | $4 000.00 |
Bruto pelnas: | $-551 000 (-13 775.00 %) |
EPS: | $-7.87 |
FY | 2022 |
Pajamos: | $305 000 |
Bruto pelnas: | $-602 000 (-197.38 %) |
EPS: | $-6.40 |
FY | 2021 |
Pajamos: | $1.25M |
Bruto pelnas: | $1.25M (100.00 %) |
EPS: | $-9.18 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Progenity, Inc.
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.